New Vaccination Guidelines May Rise Hepatitis B Infections, Study Shows

Chronic hepatitis B virus (HBV) can lead to severe liver complications. With this in mind, the Centers for Disease Control and Prevention (CDC) had previously advocated for universal vaccination of newborns. However, starting in December 2025, the Advisory Committee on Immunization Practices (ACIP) introduced a new guideline that allows for vaccination to be deferred until infants born to HBV-negative mothers reach two months of age.

In January 2026, the CDC transitioned to a 'shared clinical decision-making' model regarding HBV vaccination for these infants. This shift has sparked debate among health professionals and agencies regarding its potential impact on public health.

A Study on Vaccination Impact

Researchers at Mass General Brigham conducted a study to estimate the repercussions of these new vaccination strategies on HBV infections. Their findings indicate that delaying vaccinations could cause a 19% increase in chronic HBV cases when compared to the previous standard of immediate vaccination at birth. Meanwhile, implementing the shared decision-making strategy could lead to an astonishing 83% increase in infections.

The outcomes, detailed in the Annals of Internal Medicine, highlight a significant public health concern. “Under even the best circumstances, these recommendations may increase childhood hepatitis B infections substantially, and over half of these children may still be at risk as they grow into adulthood,” stated Dr. Amir Mohareb, the study's lead author and an infectious disease specialist at the Center for Global Health at Mass General Brigham.

Modeling the Vaccination Outcomes

Using a Markov cohort state-transition model, the team tracked health outcomes for 3.6 million births in the U.S. over a 20-year span. In these simulations, a model was built based on existing epidemiological data, which was then cross-verified against CDC estimates of pediatric HBV infections.

The model accounted for scenarios where half of the infants were vaccinated after two months, which allowed researchers to gauge the likely outcomes of the new recommendations. Vaccination was still advocated for infants whose mothers were confirmed to be HBV-positive under all scenarios studied.

Long-Term Implications of Delayed Vaccination

The projections revealed alarming statistics regarding adult susceptibility to HBV. According to the findings, if the universal vaccination at birth approach is adopted, approximately 232,000 individuals from the birth cohort would remain susceptible to HBV by age 20. In contrast, this number could swell to about 474,000 with delayed vaccination and reach around 1.8 million with the shared decision-making strategy.

This potential surge in adult susceptibility poses significant risks, as infections contracted during adulthood are more likely to cause severe conditions such as acute liver failure and liver cancer. Instances of HBV infections acquired in adulthood are also rising in various regions of the U.S., largely attributed to increased rates of injection drug use.

“Even a slight rise in childhood HBV infections can lead to large-scale public health, clinical, and economic repercussions,” noted Dr. Mohareb.

Conclusion

This study sheds light on the importance of maintaining robust public health policies to protect against hepatitis B. As the situation evolves, health authorities are urged to reconsider emphasizing universal vaccination at birth to avert potentially harmful increases in HBV infections.

For more detailed results and in-depth analysis, the full study by Dr. Mohareb and his colleagues is available in Annals of Internal Medicine.